Cargando…

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

We generated ex vivo drug-response and multiomics profiling data for a prospective series of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision medicine tumor board (FPMTB) integrated clinical, molecular, and functional data for application in clinical treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malani, Disha, Kumar, Ashwini, Brück, Oscar, Kontro, Mika, Yadav, Bhagwan, Hellesøy, Monica, Kuusanmäki, Heikki, Dufva, Olli, Kankainen, Matti, Eldfors, Samuli, Potdar, Swapnil, Saarela, Jani, Turunen, Laura, Parsons, Alun, Västrik, Imre, Kivinen, Katja, Saarela, Janna, Räty, Riikka, Lehto, Minna, Wolf, Maija, Gjertsen, Bjorn Tore, Mustjoki, Satu, Aittokallio, Tero, Wennerberg, Krister, Heckman, Caroline A., Kallioniemi, Olli, Porkka, Kimmo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762335/ https://www.ncbi.nlm.nih.gov/pubmed/34789538 http://dx.doi.org/10.1158/2159-8290.CD-21-0410

Ejemplares similares

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
por: Yadav, Bhagwan, et al.
Publicado: (2014)

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2020)

Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose–response data
por: Mpindi, John-Patrick, et al.
Publicado: (2015)

Breeze: an integrated quality control and data analysis application for high-throughput drug screening
por: Potdar, Swapnil, et al.
Publicado: (2020)

Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia
por: Hohtari, Helena, et al.
Publicado: (2022)

Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia
por: White, Brian S., et al.
Publicado: (2021)

Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data
por: Potdar, Swapnil, et al.
Publicado: (2023)

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
por: Eldfors, S, et al.
Publicado: (2017)

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
por: Malani, D, et al.
Publicado: (2017)

Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling
por: Kuusanmäki, Heikki, et al.
Publicado: (2017)

P409: BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA
por: Vänttinen, Ida, et al.
Publicado: (2023)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
por: Pietarinen, Paavo O., et al.
Publicado: (2017)

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types
por: Majumder, Muntasir M., et al.
Publicado: (2020)

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2022)

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
por: Pietarinen, P O, et al.
Publicado: (2015)

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
por: Dufva, Olli, et al.
Publicado: (2018)

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
por: Ianevski, Aleksandr, et al.
Publicado: (2021)

RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
por: Adnan Awad, Shady, et al.
Publicado: (2020)

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2023)

Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer
por: Kangaspeska, Sara, et al.
Publicado: (2016)

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
por: Yadav, Bhagwan, et al.
Publicado: (2015)

Corrigendum to “Searching for drug synergy in complex dose–response landscapes using an interaction potency model” [Comput. Struct. Biotechnol. J. 13 (2015) 504–513]
por: Yadav, Bhagwan, et al.
Publicado: (2017)

Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL
por: Hohtari, Helena, et al.
Publicado: (2019)

Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer
por: Tang, Jing, et al.
Publicado: (2019)

The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia
por: Kumar, Ashwini, et al.
Publicado: (2017)

Comparison of Affymetrix data normalization methods using 6,926 experiments across five array generations
por: Autio, Reija, et al.
Publicado: (2009)

Novel Screening Method Identifies PI3Kα, mTOR, and IGF1R as Key Kinases Regulating Cardiomyocyte Survival
por: Elmadani, Manar, et al.
Publicado: (2019)

Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis
por: Khan, Suleiman A., et al.
Publicado: (2014)

Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing
por: Majumder, Muntasir Mamun, et al.
Publicado: (2017)

Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation
por: Andersson, E I, et al.
Publicado: (2013)

P1228: GENOME-WIDE CRISPR-CAS9 SCREENING IDENTIFIES THERAPEUTIC TARGETS FOR MATURE T-CELL MALIGNANCIES
por: Timonen, Sanna, et al.
Publicado: (2023)

Discovery of MINC1, a GTPase-Activating Protein Small Molecule Inhibitor, Targeting MgcRacGAP
por: van Adrichem, Arjan J., et al.
Publicado: (2015)

Normalized Augmented Inverse Probability Weighting with Neural Network Predictions
por: Rostami, Mehdi, et al.
Publicado: (2022)

Targeted L(1)-Regularization and Joint Modeling of Neural Networks for Causal Inference
por: Rostami, Mehdi, et al.
Publicado: (2022)

Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways
por: Tang, Jing, et al.
Publicado: (2013)

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
por: Gautam, Prson, et al.
Publicado: (2016)

What is synergy? The Saariselkä agreement revisited
por: Tang, Jing, et al.
Publicado: (2015)

From drug response profiling to target addiction scoring in cancer cell models
por: Yadav, Bhagwan, et al.
Publicado: (2015)

In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL
por: Laukkanen, S, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_05bb612t6s2bnjbkn424l2ki2b